Enzymotec Ltd.'s Comment on Sales, Marketing and Customers
We sell our nutrition products to manufacturers of branded products in different
markets around the world. For example, we have developed relationships with infant
formula manufacturers who partner with us in bringing our ingredients for infant
formula to the end-user market. With respect to our other Nutrition products,
we target customers that have a significant presence in the vitamin and mineral
supplement, or VMS, industry within their geographic markets. In our VAYA Pharma
segment, the majority of our products are marketed directly to physicians by our
dedicated sales personnel, but we have also partnered with pharmaceutical companies
to provide our products outside of the United States, Singapore and Hong Kong.
Nutrition Segment
AL, our Swedish joint venture which is 50% owned by us and 50% owned by AAK,
seeks to position InFat as a strategic ingredient that enables its customers
to strengthen their premium brands of infant formula.
Sn-2 palmitate has been incorporated in infant formula products by companies
such as Danone, Nestlé, Wyeth and Heinz. AL is a major supplier of the
sn-2 palmitate in the market. AL also seeks to target additional infant formula
manufacturers and brands to incorporate the InFat products into their products.
The other customers in our Nutrition segment include leading VMS manufacturers
and retailers. We target customers with well-developed marketing and distribution
infrastructure, strong relationships with and knowledge of their end-customers,
awareness of global industry trends and scientific expertise in our fields.
We are currently seeking to establish strategic relationships with customers
that market and sell their products to mass market retailers.
VAYA Pharma Segment
In the United States, Singapore and Hong Kong, the marketing of our VAYA Pharma
products are carried out directly by our dedicated sales personnel , and such
products are distributed by pharmaceutical wholesalers, by our on-line pharmacy
and in some cases by physicians directly to end users. Outside of the United
States, Singapore and Hong Kong, where we are not developing our own specialized
marketing and sales staff of medical representatives, we seek to partner with
leading providers of pharmaceuticals and other health products in specific geographic
markets by licensing our VAYA Pharma brands, often on an exclusive basis, in
order to leverage our partners’ market presence and distribution capabilities.
To date, we have partnered with Teva Pharmaceutical Industries Ltd. in Israel
and Atlantis Ilac in Turkey. We do not currently derive material revenues from
these arrangements.
Sources:
Enzymotec Ltd.’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Enzymotec Ltd.’s corporate clients.
For your research, we’ve provided 9 tables on Enzymotec Ltd. corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
